NMDA receptors as targets for drug action in neuropathic pain

European Journal of Pharmacology

Volumn 429, Issue 1-3, 2001, Pages 71-78

  Parsons, Chris G ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Chronic; NMDA receptor; Opioid tolerance; Pain

Indexed keywords

(4 HYDROXYPHENYL)METHYL 4 (PHENYLMETHYL) 1 PIPERIDINEPROPANOL; 1 AMINOCYCLOPROPANECARBOXYLIC ACID; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 3,3 BIS(3 FLUOROPHENYL) N METHYLPROPYLAMINE; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; 4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 6,7 DIMETHYL 5 NITRO 2,3 QUINOXALINEDIONE; 7 CHLORO 1,2,5,10 TETRAHYDRO 4 HYDROXY 2 (4 METHOXY 2 METHYLPHENYL)PYRIDAZINO[4,5 B]QUINOLINE 1,10 DIONE; 8 CHLORO 4 HYDROXY 1 OXO 1,2 DIHYDROPYRIDAZINO[4,5]QUINOLINE 5 OXIDE CHOLINE; AMANTADINE; DEXANABINOL; DEXTROMETHORPHAN; DEXTROMETHORPHAN PLUS MORPHINE; DIZOCILPINE; GLUTAMATE RECEPTOR ANTAGONIST; GLYCINE; IONOTROPIC RECEPTOR; KETAMINE; LANICEMINE; MEMANTINE; MORPHINE; MRZ 2 576; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERAMEXANE; OPIATE; PHENCYCLIDINE; POLYAMINE; REMACEMIDE; STRYCHNINE; TRAXOPRODIL; UNCLASSIFIED DRUG;

ALLODYNIA; AMNESIA; ANALGESIA; ANTINOCICEPTION; ATAXIA; BLOOD BRAIN BARRIER; CHRONIC PAIN; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERANCE; EXCITATORY POSTSYNAPTIC POTENTIAL; HUMAN; HYPERALGESIA; INFLAMMATION; MOTOR DYSFUNCTION; NEUROPATHY; NEUROTRANSMISSION; NONHUMAN; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR SENSITIVITY; REVIEW; VISCERAL PAIN;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MONONEUROPATHIES; PAIN; POLYNEUROPATHIES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0035840856     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01307-3     Document Type: Review

References (96)

1. The effect of ketamine on stimulation of primary and secondary hyperalgesic areas induced by capsaicin - A double-blind, placebo-controlled, human experimental study
2. The effect of N-methyl-D-aspartate antagonist (ketamine) on single and repeated nociceptive stimuli: A placebo-controlled experimental human study
3. Long-term depression of excitatory synaptic transmission and its relationship to long-term potentiation
4. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats
5. Similarities and contrasts between cerebellar LTD and hippocampal LTP
6. Synaptic plasticity: LTP and LTD
7. Effects of short-acting NMDA receptor antagonist MRZ 2/576 on morphine tolerance development in mice
8. Short-acting NMDA receptor antagonist MRZ 2/576 produces prolonged suppression of morphine withdrawal in mice
9. Update on the neurophysiology of pain transmission and modulation: Focus on the NMDA-receptor
10. Drugs acting at the strychnine-insensitive glycine receptor do not induce HSP-70 protein in the cingulate cortex
11. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: Correlation with restricted localisation of NR2B subunit in dorsal horn
12. The glycine/NMDA receptor antagonist, L-701,324 reverses isolation-induced deficits in prepulse inhibition in the rat
13. The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents
14. Activation of N-methyl-D-aspartate receptor attenuates acute responsiveness of delta-opioid receptors
15. Inflammation-induced changes in peripheral glutamate receptor populations
16. Treatment with the NMDA antagonist memantine attenuates nociceptive responses to mechanical stimulation in neuropathic rats
17. Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin
18. Evidence for the interaction of glutamate and NK1 receptors in the periphery
19. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat
20. Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine-therapeutic advantage against NMDA receptor-mediated neurotoxicity
21. A study of the dose dependency of a glycine receptor antagonist in focal ischemia
22. The N-methyl-D-aspartate antagonistic and opioid components of D-methadone antinociception in the rat spinal cord
23. The antinociceptive effect of combined systemic administration of morphine and the glycine/NMDA receptor antagonist, (+)-HA-966 in a rat model of peripheral neuropathy (Vol. 125, p. 1641, 1998)
24. Evidence for an inflammation-induced change in the local glutamatergic regulation of postganglionic sympathetic efferents
25. Memories of NMDA receptors and LTP
26. Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications
27. Intraplantar injection of dextrorphan, ketamine or memantine attenuates formalin-induced behaviors
28. Peripheral NMDA and non-NMDA glutamate receptors contribute to nociceptive behaviors in the rat formalin test
29. A cure for wind up: NMDA receptor antagonists as potential analgesics
30. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord
31. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord
32. The NMDA-antagonist ketamine for prevention and treatment of acute and chronic post-operative pain
33. The NMDA antagonist memantine blocks pain behavior in a rat model of formalin-induced facial pain
34. The effects of the clinically tested NMDA receptor antagonist memantine on carrageenan-induced thermal hyperalgesia in rats
35. The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy
36. N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development
37. N-methyl-D-aspartate attenuates opioid receptor-mediated G protein activation and this process involves protein kinase C
38. Effects of memantine and (+)-MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices
39. Antihyperalgesic effect of the N-methyl-D-aspartate receptor antagonist dextromethorphan in the oral surgery model
40. The D- and L-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord
41. Different threshold levels of postsynaptic [Ca2+](i) have to be reached to induce LTP and LTD in neocortical pyramidal cells
42. Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology
43. Wind-up of spinal cord neurones and pain sensation: Much ado about something?
44. Frequency-dependent involvement of NMDA receptors in the hippocampus: A novel synaptic mechanism
45. The use of NMDA-receptor antagonists in the treatment of chronic pain
46. MRZ 2/579, a fast kinetic NMDA receptor antagonist, delays the development of morphine tolerance in awake rats
47. Effect of systemic N-methyl-D-aspartate receptor antagonist (dextromethorphan) on primary and secondary hyperalgesia in humans
48. Glutamate participates in the peripheral modulation of thermal hyperalgesia in rats
49. NMDA receptor antagonists acting at the glycine(B) site in rat models for antipsychotic-like activity
50. 1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance
51. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy
52. Excitability changes of somatic and viscero-somatic nociceptive reflexes in the decerebrate-spinal rabbit: Role of NMDA receptors
53. Effects of a partial agonist and a full antagonist acting at the glycine site of the NMDA receptor on inflammation-induced mechanical hyperalgesia in rats
54. Excitatory amino acid receptor involvement in peripheral nociceptive transmission in rats
55. Anticonvulsant effects of the glycine/NMDA receptor ligands d-cycloserine and d-serine but not R(+)-HA-966 in amygdala-kindled rats
56. Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor glycine site antagonist
57. Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test
58. Synaptic plasticity in the hippocampus: LTP and LTD
59. NMDA and opioid receptors: Their interactions in antinociception, tolerance and neuroplasticity
60. Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy
61. Experimental mononeuropathy reduces the antinociceptive effects of morphine: Implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain
62. Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats
63. Antagonism of N-methyl-D-aspartate-evoked currents in rat cortical cultures by ARL 15896AR
64. The effect of naloxone on ketamine-induced effects on hyperalgesia and ketamine-induced side effects in humans
65. Chemically-diverse ligands at the glycineB site coupled to N-methyl-D-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice
66. The clinically available NMDA receptor antagonist memantine is antinociceptive on rat spinal neurones
67. Differential effects of N-methyl-D-aspartate receptor blockade on nociceptive somatic and visceral reflexes
68. Formalin-induced release of excitatory amino acids in the skin of the rat hindpaw
69. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: Electrophysiological, biochemical and behavioral characterization
70. Glutamate in CNS disorders as a target for drug development. An update
71. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data
72. Pharmacological modulation of opioid tolerance
73. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine
74. Clinically available NMDA antagonist, memantine, attenuates tolerance to analgesic effects of morphine in a mouse tail flick test
75. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence
76. Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists
77. The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man
78. Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy
79. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A
80. Wind-up and the NMDA receptor: From animal studies to humans
81. The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuated carrageenan-induced behavioral hyperalgesia in rats
82. Therapeutic potential of excitatory amino acid antagonists - Channel blockers and 2,3-benzodiazepines
83. Induction of long-term potentiation at spinal synapses by noxious stimulation or nerve injury
84. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: A review of current techniques and outcomes
85. Low-affinity NMDA receptor channel blockers inhibit acquisition of intravenous morphine self-administration in naive mice
86. Comparison of the effects of (+)-MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy
87. Regulation of ligand-gated ion channels by protein phosphorylation
88. Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist
89. A glycine site antagonist, ZD9379, reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion
90. Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies
91. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist (+)-MK-801
92. Excitatory amino acids and drugs of abuse: A role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence
93. NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin
94. Local treatment with the N-methyl-D-aspartate receptor antagonist ketamine, inhibit development of secondary hyperalgesia in man by a peripheral action
95. Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: Effects of modulatory receptor systems and excitatory amino acid antagonists
96. Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats